longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

R&G Pharma

301333

61.802.39% ( -1.51 )
Delay Trading: Sep 15, 13:13:24
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 50.85, above the reasonable range, cheaper than 1.28% of the time in the past 3 years, and the industry ranks 7/27, the industry Median 50.85.

50.85xP/E
¥63.31Stock price
¥1.25Earnings per share
50.85xP/E
Stock price¥63.31Earnings per share¥1.25

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
37.18x
Typical range
30.65x–43.93x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 50.85x
0133266399532

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 50.85x
0x40x80x120x160x200x
P/E ratio
Name/Symbol
300759SZPharmaron
45.75x15.51%¥78.36B
301333SZR&G Pharma
50.85x20.98%¥6.11B
301257SZClinPlus
50.76x--¥2.95B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.